{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:07:12Z","timestamp":1792642032613,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T00:00:00Z","timestamp":1338163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,10]]},"abstract":"\n Aims<\/jats:title>\n \n We examined the effects of the oral dipeptidyl peptidase\u20104 (\n DPP<\/jats:styled-content>\n \u20104) inhibitor saxagliptin on glycaemic control and pancreatic \u03b2\u2010cell mass and morphology in a mouse model of type 2 diabetes mellitus (\n T2DM<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Male\n C57BL<\/jats:styled-content>\n \/6 mice (n\u2009=\u200912\/group) aged 4 to 6\u2009weeks and weighing >15\u2009g received a high\u2010fat diet throughout this 45\u2010day study. After a 7\u2010day handling period, baseline levels of plasma glucose, plasma insulin and glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) were assessed. Animals were allocated to one of six groups: compound vehicle control, intraperitoneal streptozotocin (\n STZ<\/jats:styled-content>\n , 50\u2009mg\/kg)\u2010treated control and saxagliptin (10\u2009mg\/kg) or sitagliptin (10\u2009mg\/kg, positive control) initiated 7\u2009days before or 1\u2009day after\n STZ<\/jats:styled-content>\n administration. Endpoints included changes in body weight, food and water consumption, glucose tolerance (approximately 3 weeks post\u2010\n STZ<\/jats:styled-content>\n ), fasting glucose and HbA1c and immunohistochemical analyses of the pancreas.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Body weight, weight gain and food intake were reduced in\n STZ<\/jats:styled-content>\n versus control mice.\n DPP<\/jats:styled-content>\n \u20104 inhibitor treatment did not affect these changes, but the increase in water intake observed post\u2010\n STZ<\/jats:styled-content>\n administration was significantly attenuated with\n DPP<\/jats:styled-content>\n \u20104 inhibitors whether initiated before or after\n STZ<\/jats:styled-content>\n injury. Small but significant improvements in glycaemic control were observed with\n DPP<\/jats:styled-content>\n \u20104 inhibitors versus the\n STZ<\/jats:styled-content>\n control. Improved \u03b2\u2010cell mass and morphology were observed with saxagliptin given pre\u2010 or post\u2010\n STZ<\/jats:styled-content>\n and sitagliptin given post\u2010\n STZ<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Saxagliptin mitigated damage to \u03b2\u2010cells and improved glycaemic control in this mouse model of\n T2DM<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/j.1463-1326.2012.01619.x","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T03:25:13Z","timestamp":1336447513000},"page":"918-926","source":"Crossref","is-referenced-by-count":45,"title":["Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic \u03b2\u2010cell mass in a streptozotocin\u2010induced mouse model of type 2 diabetes"],"prefix":"10.1111","volume":"14","author":[{"given":"S. M.","family":"Poucher","sequence":"first","affiliation":[{"name":"CVGI Discovery iMED AstraZeneca Pharmaceuticals Macclesfield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cheetham","sequence":"additional","affiliation":[{"name":"RenaSci Consultancy Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Francis","sequence":"additional","affiliation":[{"name":"ASTL AstraZeneca Pharmaceuticals Charnwood UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zinker","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Vickers","sequence":"additional","affiliation":[{"name":"RenaSci Consultancy Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,28]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011. Atlanta GA: US Department of Health and Human Services Centers for Disease Control and Prevention 2011."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2009.09076"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0467"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X178766"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903456046"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.10.007"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0699"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090555"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.5.463"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2006.024"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0015"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0703"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0416-z"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970422"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2006.12.009"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00850.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903178735"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1035"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.10.012"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01180.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.01.016"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20100372"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0058"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1261929"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.027"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1602"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.3.741"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01354.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90027-0"},{"key":"e_1_2_7_34_1","first-page":"451","article-title":"Animal models in type 2 diabetes research: an overview","volume":"125","author":"Srinivasan K","year":"2007","journal-title":"Indian J Med Res"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2365-4"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01291.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20090047"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3280a02f65"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104345"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0631828100"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0063"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.143966"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1137"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.305359"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP10112.RA"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2012.01619.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2012.01619.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:57:47Z","timestamp":1761868667000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2012.01619.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,28]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1463-1326.2012.01619.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01619.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,28]]}}}